menu

Medical Program: Locally advanced prostate cancer, muscle-invasive bladder cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer 

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette-Guérin in patients with Bacillus Calmette-Guérin-naive high-risk non–muscle-invasive bladder cancer.

    Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.

Facebook Comments

Recommended
Details
Comments
  • Overview

    SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette-Guérin in patients with Bacillus Calmette-Guérin-naive high-risk non–muscle-invasive bladder cancer.

    Advancements in genitourinary cancers are evolving rapidly, and it is often challenging for busy urologists and urologic oncologists to stay current with these emerging data, which can lead to suboptimal outcomes in their patients. In this activity, expert faculty assess key data in locally advanced prostate cancer and bladder cancer and best practices for the integration of these findings to clinical practice.

Facebook Comments

Schedule26 May 2024